Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DCPrime Appoints CEO and CMO and Expands Supervisory Board

Published: Tuesday, October 09, 2012
Last Updated: Tuesday, October 09, 2012
Bookmark and Share
Company appoints Marcel Zwaal and Dr. Anthony Hall as CEO and CMO respectively.

Cancer vaccine company DCPrime has announced the appointments of Marcel Zwaal as Chief Executive Officer, and of Dr. Anthony Hall as Chief Medical Officer.

Dr. Anthony Hall has 18 years of experience in clinical drug development, in particular in orphan drug indications.

Dr. Ada Kruisbeek, founder of DCPrime and since the start of the company active in a dual role as CEO and Chief Scientific Officer, will continue to build and expand the company’s product platform technology as CSO.

“DCPrime is entering a new stage of its development with an on-going Phase I/IIa trial in Acute Myeloid Leukemia and a Phase II efficacy trial to start in the course of 2013,” said Michel Briejer, Chairman of DCPrime’s Supervisory Board.

Briejer continued, “With Marcel stepping up from Chief Business Officer to the position of CEO, Ada focusing on reinforcing and expanding the platform, and Tony joining to move our clinical programs forward, DCPrime has a formidable team in place to bring the company’s exciting new class of off-the-shelf cancer vaccines to market.”

DCPrime also appointed Bart Klein to its Supervisory Board. Mr. Klein, former Executive Vice President Intellectual Property & Legal Affairs at Crucell, brings 23 years of experience in intellectual property and licensing.

In addition to Mr. Klein, the Supervisory Board consists of Onno van de Stolpe, CEO of Galapagos, Dr. Herbert Heyneker, one of the most distinguished scientist entrepreneurs in the biotech industry, Dr. Leon Hooftman who, following a high-profile career in clinical development, currently is Chief Medical Officer of Synthon, and Dr. Michel Briejer, chairman and partner of Thuja Capital, DCPrime’s cornerstone investor.

“I am delighted to take the helm from Ada, and be given the opportunity to lead the charge to bring DCPrime’s cancer vaccines to patients with real unmet medical needs,” said Marcel Zwaal, CEO.

Zwaal continued, “Supported by our dedicated board members, our management team now has all the capabilities to make a push forward, and capitalize on our first-in-class product platform to develop effective cancer vaccines.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

European Medicines Agency Approves Orphan Medicinal Product Application of DCPrime's AML Vaccine
DCPrime's AML vaccine has potential to improve the survival of patients with leukemia.
Thursday, February 02, 2012
Scientific News
First Large-Scale Proteogenomic Study of Breast Cancer
The study offers understanding of potential therapeutic targets.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Paper Filter Can Remove Viruses from Water
A new paper filter can purify water from viruses, even the most difficult and contagious.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Mimicking Evolution to Create Novel Proteins
A study by researchers in the Kuhlman lab offers a new route to design the 'cellular machines' needed to understand and battle diseases.
Antibody Therapy Opens Door to Potential New Treatment for HIV
Researchers at Rockefeller University show how a broadly neutralizing antibody could be used to help fight HIV.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!